Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17863796 | 0.90 | PIK3C3 (0.42) | L3MBTL1PIK3C3MAPKAPK2JAK2JAK1 | |
| SCHEMBL17840582 | 0.88 | TYK2 (0.41) | L3MBTL1PIK3C3GRM5MAPKAPK2JAK2 | |
| SCHEMBL30365666 | 0.88 | TYK2 (0.41) | L3MBTL1PIK3C3GRM5MAPKAPK2JAK2 | |
| SCHEMBL17840563 | 0.87 | CYP1A2 (0.40) | L3MBTL1PIK3C3AAK1CYP3A4 | |
| SCHEMBL17840827 | 0.86 | L3MBTL1 (0.36) | L3MBTL1PIK3C3MAPKAPK2JAK2JAK1 | |
| SCHEMBL17840751 | 0.86 | AAK1 (0.40) | L3MBTL1PIK3C3MAPKAPK2JAK2JAK1 | |
| SCHEMBL17840655 | 0.85 | AAK1 (0.38) | L3MBTL1PIK3C3MAPKAPK2AAK1CYP3A4 | |
| SCHEMBL17840721 | 0.85 | AAK1 (0.37) | L3MBTL1MAPKAPK2AAK1CYP3A4 | |
| SCHEMBL17871067 | 0.84 | L3MBTL1 (0.34) | L3MBTL1PIK3C3MAPKAPK2JAK2JAK1 | |
| SCHEMBL17871069 | 0.84 | L3MBTL1 (0.34) | L3MBTL1PIK3C3MAPKAPK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | L3MBTL1 903/4885PIK3C3 2608/4885GRM5 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.